Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Burtness

Showing results (101-110 of 184) with videos related to

Pageof 19
Sort By:
Human Genetics|August 11, 2014
Predicting survival in head and neck squamous cell carcinoma from TP53 mutationDavid L Masica, Shuli Li, Christopher Douville, et al.
Annals of Surgical Oncology|September 28, 2011
Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun, Harry S Cooper, Steven J Cohen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 26, 2020
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancerKenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 28, 2009
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerBarbara Burtness, Milan Anadkat, Surendra Basti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2017
Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck CancerAsel Biktasova, Michael Hajek, Andrew Sewell, et al.
Oral Oncology|March 31, 2018
Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancerJacqueline R Kelly, Henry S Park, Yi An, et al.
Oncotarget|May 31, 2022
NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancerTravis P Schrank, Andrew C Prince, Tejas Sathe, et al.
Future Oncology (London, England)|February 17, 2022
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study designJean Bourhis, Barbara Burtness, Lisa F Licitra, et al.
Oral Oncology|March 31, 2019
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinomaNnamdi Eze, Ju-Whei Lee, Dong-Hua Yang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancerZiwei Yu, Paul M Weinberger, Clarence Sasaki, et al.
Pageof 19

Showing results (101-110 of 184) with videos related to

Sort By:
Pageof 19
Human Genetics|August 11, 2014
Predicting survival in head and neck squamous cell carcinoma from TP53 mutationDavid L Masica, Shuli Li, Christopher Douville, et al.
Annals of Surgical Oncology|September 28, 2011
Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun, Harry S Cooper, Steven J Cohen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 26, 2020
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancerKenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 28, 2009
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerBarbara Burtness, Milan Anadkat, Surendra Basti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2017
Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck CancerAsel Biktasova, Michael Hajek, Andrew Sewell, et al.
Oral Oncology|March 31, 2018
Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancerJacqueline R Kelly, Henry S Park, Yi An, et al.
Oncotarget|May 31, 2022
NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancerTravis P Schrank, Andrew C Prince, Tejas Sathe, et al.
Future Oncology (London, England)|February 17, 2022
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study designJean Bourhis, Barbara Burtness, Lisa F Licitra, et al.
Oral Oncology|March 31, 2019
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinomaNnamdi Eze, Ju-Whei Lee, Dong-Hua Yang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancerZiwei Yu, Paul M Weinberger, Clarence Sasaki, et al.
Pageof 19